Tags

Type your tag names separated by a space and hit enter

Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
Neurosci Biobehav Rev. 2006; 30(1):1-23.NB

Abstract

It is well recognised that patients with Parkinson's disease exhibit cognitive deficits, even in the earliest disease stages. Whereas, L-DOPA therapy in early Parkinson's disease is accepted to improve the motor symptoms, the effects on cognitive performance are more complex: both positive and negative effects have been observed. The purpose of the present article is to review the effects of L-DOPA medication in Parkinson's disease on cognitive functions in the broad domains of cognitive flexibility and working memory. The review places the effects in Parkinson's disease within a framework of evidence from studies with healthy human volunteers, rodents and non-human primates as well as computational modeling work. It is suggested that beneficial or detrimental effects of L-DOPA are observed depending on task demands and basal dopamine levels in distinct parts of the striatum. The study of the beneficial and detrimental cognitive effects of L-DOPA in Parkinson's disease has substantial implications for the understanding and treatment development of cognitive abnormalities in Parkinson's disease as well as normal health.

Authors+Show Affiliations

Helen Wills Neuroscience Institute, University of California, 132 Barker Hall, Berkeley, USA. roshanco@berkeley.edu

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

15935475

Citation

Cools, Roshan. "Dopaminergic Modulation of Cognitive Function-implications for L-DOPA Treatment in Parkinson's Disease." Neuroscience and Biobehavioral Reviews, vol. 30, no. 1, 2006, pp. 1-23.
Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev. 2006;30(1):1-23.
Cools, R. (2006). Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neuroscience and Biobehavioral Reviews, 30(1), 1-23.
Cools R. Dopaminergic Modulation of Cognitive Function-implications for L-DOPA Treatment in Parkinson's Disease. Neurosci Biobehav Rev. 2006;30(1):1-23. PubMed PMID: 15935475.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. A1 - Cools,Roshan, Y1 - 2005/06/01/ PY - 2004/08/31/received PY - 2005/03/15/revised PY - 2005/03/21/accepted PY - 2005/6/7/pubmed PY - 2006/3/22/medline PY - 2005/6/7/entrez SP - 1 EP - 23 JF - Neuroscience and biobehavioral reviews JO - Neurosci Biobehav Rev VL - 30 IS - 1 N2 - It is well recognised that patients with Parkinson's disease exhibit cognitive deficits, even in the earliest disease stages. Whereas, L-DOPA therapy in early Parkinson's disease is accepted to improve the motor symptoms, the effects on cognitive performance are more complex: both positive and negative effects have been observed. The purpose of the present article is to review the effects of L-DOPA medication in Parkinson's disease on cognitive functions in the broad domains of cognitive flexibility and working memory. The review places the effects in Parkinson's disease within a framework of evidence from studies with healthy human volunteers, rodents and non-human primates as well as computational modeling work. It is suggested that beneficial or detrimental effects of L-DOPA are observed depending on task demands and basal dopamine levels in distinct parts of the striatum. The study of the beneficial and detrimental cognitive effects of L-DOPA in Parkinson's disease has substantial implications for the understanding and treatment development of cognitive abnormalities in Parkinson's disease as well as normal health. SN - 0149-7634 UR - https://www.unboundmedicine.com/medline/citation/15935475/Dopaminergic_modulation_of_cognitive_function_implications_for_L_DOPA_treatment_in_Parkinson's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0149-7634(05)00054-0 DB - PRIME DP - Unbound Medicine ER -